论文部分内容阅读
目的:分析利奈唑胺与万古霉素治疗革兰氏阳性菌血症效果比较的系统评价。方法:选取我院2015年2月~2017年1月收治的革兰氏阳性菌血症的患者80例作为研究对象。将80例患者按照治疗方式的不同分为两组,实验组患者40例,对照组患者40例。实验组患者采取利奈唑胺治疗,对照组患者采取万古霉素治疗,对比两种治疗方式的治疗效果。结果:实验组患者治疗有效率为65%,对照组患者的治疗有效率为67.5%,两组比较无统计学差异,P>0.05。对照组的肾功能不全发生率明显高于实验组;实验组患者的血小板减少症发生率明显高于对照组,P<0.05,有统计学差异。结论:采用利奈唑胺和万古霉素在治疗革兰氏阳性菌血症疾病中,治疗效果无差异,其中,利奈唑胺具有更好的耐受性,较小的肾毒性,对于万古霉素耐药患者和肾功能不全的患者,可以采用利奈唑胺进行治疗。根据患者的临床情况,选择合适的药物进行治疗,从而提高患者的治疗效果和预后效果。
OBJECTIVE: To evaluate the systematic comparison of the efficacy of linezolid and vancomycin in the treatment of Gram-positive bacteremia. Methods: Eighty patients with Gram-positive bacteremia admitted from February 2015 to January 2017 in our hospital were selected as the research object. Eighty patients were divided into two groups according to the different treatment methods. There were 40 patients in the experimental group and 40 patients in the control group. Patients in the experimental group were treated with linezolid, while those in the control group were treated with vancomycin. The therapeutic effects of the two treatments were compared. Results: The effective rate of treatment in experimental group was 65%, while that in control group was 67.5%. There was no significant difference between the two groups (P> 0.05). The incidence of renal insufficiency in the control group was significantly higher than the experimental group; the incidence of thrombocytopenia in the experimental group was significantly higher than that in the control group, P <0.05, with statistical significance. CONCLUSIONS: Linezolid and vancomycin have no difference in the treatment of Gram-positive bacteremia, with linezolid having better tolerability and less nephrotoxicity than vancomycin Resistant patients and patients with renal insufficiency, linezolid can be used for treatment. According to the patient’s clinical condition, select the appropriate drug for treatment, thereby enhancing the patient’s treatment and prognosis.